Risk Stratification and MRD-driven Maintenance for MM After ASCT

Who May Qualify: 1. Newly diagnosed multiple myeloma with a history of a minimum of 4 cycles of induction therapy, have received high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) within 12 months of the start of induction therapy, and be within 6 months of ASCT. 2. Must have a partial response (PR) or better response before maintenance. 3. Must have an Eastern Cooperative Oncology Group performance status score of 0, 1, or 2. 4. This study allows for post-ASCT consolidation therapy. 5. white blood cell count (ANC) at least 1.0 x 10\^9/L, Hb ≥ 85 g/L PLT ≥ 75 x 10\^9/L (if BMPC \< 50%) or PLT ≥ 50 x 10\^9/L (if BMPC ≥ 50%). 6. No active infection. 7. a).TBIL\<1.5 x upper limit of normal (ULN) (\<3 x ULN in patients with Gilbert's syndrome); b).AST and ALT \<3 x ULN.; c. kidney function (creatinine clearance) at least 45mL/min. Who Should NOT Join This Trial: 1. Must not refractory or non-tolerate to lenalidomide in Arm A. 2. Must not refractory or non-tolerate to lenalidomide and daratumumab in Arm B. 3. Must not have progressed on multiple myeloma (MM) therapy before screening 4. Chronic obstructive pulmonary disease (COPD) with FEV1 less than 50 % of predicted normal； 5. Have known moderate or severe persistent asthma within the past 2 years or current uncontrolled asthma of any classification 6. History of stroke or serious thrombotic event within 12 months prior to screening. Always talk to your doctor about whether this trial is right for you.